STEVENS J
GenericsSTEVENS J is a generic drug manufacturer focused on Oncology, Metabolic, Infectious Disease. Key products include THYQUIDITY.
STEVENS J's Key Drugs
STEVENS J's core commercial portfolio centers on THYQUIDITY, spanning Oncology and Metabolic — its most strategically important drugs approved in the last 15 years.
STEVENS J's Recent FDA Approvals
New NDA/BLA approvals for STEVENS J over the last two years — novel drugs only, excluding generics and label supplements.
STEVENS J's Therapeutic Areas
STEVENS J's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Metabolic, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
STEVENS J's Top Competitors
STEVENS J's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
STEVENS J Pipeline Snapshot
Active clinical trials for STEVENS J across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • THYQUIDITY leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1988-03-17
- Latest
- 2026-06-18
- Applications
- 13